Mitotic counts provide additional prognostic information in grade II mammary carcinoma.
The ability to predict how long a patient diagnosed with breast cancer is likely to survive is still imprecise, despite numerous studies which have identified potential prognostic markers. The "established" markers such as nodal status, tumour size, and histological grade have been used for many years and certainly provide some degree of accuracy upon which treatment can be based. However, women with similar prognostic features can vary significantly in their outcome and very few of the newly identified markers provide information that is sufficiently useful to warrant the time and expense spent on their evaluation. In a cohort of 145 women, an assessment has been made of whether knowledge of the proliferative activity of grade II infiltrating ductal breast carcinomas can improve the accuracy of predicting clinical outcome for individual patients. Use of the mitotic count (MC), which was assessed as part of the grading system, enabled patients to be stratified into "good" and "bad" prognostic groups. The measurement of S-phase fraction using flow cytometry gave a similar result, but has the disadvantage that the technique requires specialized equipment. The evaluation of Ki-67 expression using immunohistochemistry was of no additional prognostic value in this defined group. It is proposed that MC, used once to establish grade, could be used again amongst the grade II tumours to improve the accuracy of prognosis and thus influence treatment strategies with minimal additional effort or expense.
Lynch
J
J
Guy's, Kings and St Thomas School of Medicine, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK.
Pattekar
R
R
Barnes
D M
DM
Hanby
A M
AM
Camplejohn
R S
RS
Ryder
K
K
Gillett
C E
CE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000401:mortality / Q000473:pathology* / Q000556:secondary; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D016015:Logistic Models; D008207:Lymphatic Metastasis; D008875:Middle Aged; D008940:Mitotic Index; D010865:Pilot Projects; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D016196:S Phase; D015996:Survival Rate
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D011960:Receptors, Estrogen